Pharma Industry News

Celltrion’s infliximab biosimilar to be tested for COVID-19

Infliximab has been chosen because of its effective role in treating autoimmune and inflammatory conditions and established safety profileOriginal Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]